

# Paul C Lorigan

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6642459/paul-c-lorigan-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

231  
papers

39,366  
citations

60  
h-index

198  
g-index

256  
ext. papers

46,194  
ext. citations

8.2  
avg, IF

6.47  
L-index

#	Paper	IF	Citations
231	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 711-23	59.2	10591
230	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2507-16	59.2	5851
229	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2521-32	59.2	3792
228	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 375-84	21.7	1881
227	Improved overall survival in melanoma with combined dabrafenib and trametinib. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 30-9	59.2	1723
226	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 107-14	59.2	1634
225	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1789-1801	59.2	918
224	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 323-32	21.7	753
223	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , <b>2017</b> , 390, 1853-1862	40	703
222	Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 616-22	2.2	607
221	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet, The</i> , <b>2008</b> , 372, 117-126	40	496
220	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1239-1251	21.7	425
219	Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 576-84	2.2	350
218	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3740-3748	2.2	319
217	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 226-235	2.2	302
216	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 383-390	2.2	273
215	Revised U.K. guidelines for the management of cutaneous melanoma 2010. <i>British Journal of Dermatology</i> , <b>2010</b> , 163, 238-56	4	259

214	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1116-1125	21.7	253
213	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. <i>Cancer Discovery</i> , <b>2013</b> , 3, 158-67	24.4	249
212	Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5426-34	2.2	225
211	Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3144-50	2.2	209
210	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 449-58	7.4	207
209	Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1042-8	12.9	201
208	Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4012-9	2.2	197
207	Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 808-16	5.8	191
206	Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 53-61	2.2	189
205	Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. <i>European Journal of Cancer</i> , <b>2017</b> , 83, 247-257	7.5	181
204	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , <b>2016</b> , 6, 286-99	24.4	172
203	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 519-527	13.4	148
202	Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. <i>Cancer Cell</i> , <b>2015</b> , 27, 85-96	24.3	147
201	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotential. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1191-9	3.5	141
200	Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4787-92	2.2	136
199	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 733-40	21.7	135
198	Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 822-8	8.7	121
197	Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). <i>Annals of Oncology</i> , <b>2013</b> , 24, 2694-2698	10.3	119

196	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , <b>2016</b> , 53, 125-34	7.5	115
195	Adjuvant interferon- $\alpha$ for the treatment of high-risk melanoma: An individual patient data meta-analysis. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 171-183	7.5	114
194	Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 1582-90	4.3	107
193	Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2598-603	2.2	101
192	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , <b>2016</b> , 76, 925-45	12.1	100
191	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 750-5	8.7	99
190	Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2551-7	2.2	99
189	BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. <i>Science Signaling</i> , <b>2014</b> , 7, ra30	8.8	95
188	Revised UK guidelines for the management of cutaneous melanoma 2010. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , <b>2010</b> , 63, 1401-19	1.7	92
187	A randomised, phase II study of intetumumab, an anti- $\alpha$ -integrin mAb, alone and with dacarbazine in stage IV melanoma. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 346-52	8.7	91
186	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. <i>Supportive Care in Cancer</i> , <b>2008</b> , 16, 201-8	3.9	79
185	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. <i>Lancet Oncology</i> , <b>2014</b> , 15, 620-30	21.7	78
184	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , <b>2017</b> , 5, 390-390	3.2	78
183	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3925-3936	2.2	78
182	PD-L1 expression as a potential predictive biomarker. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1285-7	21.7	75
181	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. <i>Nature Medicine</i> , <b>2015</b> , 21, 741-50	50.5	75
180	Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 666-74	9.7	73
179	A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue. <i>Lung Cancer</i> , <b>2011</b> , 71, 94-102	5.9	72

178	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology, The</i> , <b>2005</b> , 6, 773-9	21.7	71
177	Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy. <i>Nature Cancer</i> , <b>2020</b> , 1, 210-221	15.4	65
176	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8502-8502	2.2	65
175	Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1993-2004	8.9	64
174	Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. <i>Melanoma Research</i> , <b>2014</b> , 24, 40-6	3.3	61
173	TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. <i>British Journal of Cancer</i> , <b>2003</b> , 89, 1123-9	8.7	61
172	The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. <i>Annals of Oncology</i> , <b>2010</b> , 21, 2023-2028	10.3	60
171	Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. <i>British Journal of Haematology</i> , <b>2002</b> , 116, 291-8	4.5	60
170	Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , <b>1999</b> , 35, 410-2	7.5	58
169	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 643-654	21.7	58
168	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , <b>2018</b> , 91, 116-124	7.5	54
167	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. <i>Annals of Oncology</i> , <b>2014</b> , 25, 968-74	10.3	53
166	Management of small cell lung cancer: recent developments for optimal care. <i>Drugs</i> , <b>2012</b> , 72, 471-90	12.1	52
165	Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. <i>Annals of Oncology</i> , <b>2015</b> , 26, 33-39	10.3	50
164	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). <i>Annals of Oncology</i> , <b>2006</b> , 17, 1111-9	10.3	50
163	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110,	9.7	49
162	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 297-304	21.7	49
161	Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. <i>British Journal of Cancer</i> , <b>2001</b> , 84, 499-503	8.7	48

160	Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. <i>Melanoma Research</i> , <b>2015</b> , 25, 432-42	3.3	47
159	Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2052-2058	10.3	46
158	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. <i>Lung Cancer</i> , <b>2011</b> , 72, 378-83	5.9	46
157	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. <i>Health and Quality of Life Outcomes</i> , <b>2012</b> , 10, 66	3	45
156	Monitoring tumour cells in the peripheral blood of small cell lung cancer patients. <i>Cytometry</i> , <b>2002</b> , 50, 160-7		45
155	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. <i>Cancer</i> , <b>2001</b> , 92, 601-8	6.4	44
154	Gender and survival in malignant tumours. <i>Cancer Treatment Reviews</i> , <b>2001</b> , 27, 201-9	14.4	44
153	Investigation of female survival benefit in metastatic melanoma. <i>British Journal of Cancer</i> , <b>1999</b> , 80, 2025-33	5.33	44
152	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , <b>2016</b> , 2016,	1.4	44
151	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 863-73	7.4	43
150	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , <b>2019</b> , 116, 148-157	7.5	42
149	Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?. <i>Experimental Dermatology</i> , <b>2008</b> , 17, 383-94	4	42
148	Phase I study of IMG901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. <i>Investigational New Drugs</i> , <b>2016</b> , 34, 290-9	4.3	41
147	Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMG901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 68-76.e2	4.9	40
146	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , <b>2020</b> , 130, 126-138	7.5	39
145	No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1140-58	7.9	39
144	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , <b>2011</b> , 105, 353-9	8.7	39
143	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 442-7	8.7	39

142	Characteristics of women with recurrent molar pregnancies. <i>Gynecologic Oncology</i> , <b>2000</b> , 78, 288-92	4.9	39
141	Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. <i>Journal of Investigative Dermatology</i> , <b>2002</b> , 119, 1165-71	4.3	36
140	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. <i>Lung Cancer</i> , <b>2015</b> , 88, 117-23	5.9	35
139	O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 1250-6	8.7	35
138	High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. <i>British Journal of Cancer</i> , <b>2005</b> , 93, 620-1	8.7	35
137	Management of small-cell lung cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16 Suppl 2, ii235-9	10.3	35
136	Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 185-90	2.2	34
135	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1843-1852	10.3	33
134	Modern management of small-cell lung cancer. <i>Drugs</i> , <b>2007</b> , 67, 2135-52	12.1	33
133	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 836-847	21.7	33
132	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , <b>2019</b> , 119, 168-178	7.5	32
131	Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 779-89	3.9	32
130	Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 582-590	6.1	32
129	Considerations in developing and delivering a nonpharmacological intervention for symptom management in lung cancer: the views of patients and informal caregivers. <i>Journal of Pain and Symptom Management</i> , <b>2012</b> , 44, 831-42	4.8	32
128	Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). <i>European Journal of Cancer</i> , <b>2012</b> , 48, 2175-82	7.5	32
127	Protocol for the CONVERT trial-Concurrent ONce-daily VErus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer. <i>BMJ Open</i> , <b>2016</b> , 10, e008112	3	32
126	A Phase 3 Randomized, Open-Label Study of Nivolumab (Anti-Pd-1; Bms-936558; Ono-4538) Versus Investigator'S Choice Chemotherapy (Icc) in Patients with Advanced Melanoma After Prior Anti-Ctla-4 Therapy. <i>Annals of Oncology</i> , <b>2014</b> , 25, v1	10.3	31
125	Radiotherapy for small-cell lung cancer-Where are we heading?. <i>Lung Cancer</i> , <b>2009</b> , 63, 307-14	5.9	31

124	Improving outcomes in advanced malignant melanoma: update on systemic therapy. <i>Drugs</i> , <b>2005</b> , 65, 733-43	12.1	31
123	The role of positron emission tomography in management of small cell lung cancer. <i>Lung Cancer</i> , <b>2011</b> , 73, 121-6	5.9	30
122	Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2136-44	2.2	29
121	Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 2322-30	7.5	27
120	The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. <i>Annals of Oncology</i> , <b>2010</b> , 21, 232-237	10.3	27
119	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , <b>2019</b> , 116, 207-215	7.5	26
118	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>Oncolmmunology</i> , <b>2018</b> , 7, e1433516	7.2	26
117	Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery. <i>Cancer Research</i> , <b>2014</b> , 74, 6390-6396	10.1	26
116	Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. <i>Melanoma Research</i> , <b>2009</b> , 19, 333-4	3.3	26
115	Lung cancer after treatment for breast cancer. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 1184-92	21.7	25
114	Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. <i>Melanoma Research</i> , <b>2006</b> , 16, 11-22	3.3	25
113	Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. <i>Clinical Oncology</i> , <b>2002</b> , 14, 361-6	2.8	24
112	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. <i>Lung Cancer</i> , <b>2012</b> , 76, 72-7	5.9	23
111	Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 1451-9	8.7	23
110	Does adjuvant vaccine therapy really have activity in malignant melanoma?. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4693; author reply 4693-5	2.2	23
109	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , <b>2018</b> , 91, 168-170	7.5	23
108	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3205-14	7.5	22
107	Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. <i>Lung Cancer</i> , <b>2009</b> , 64, 60-5	5.9	22

106	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1437-48	3.5	21
105	Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. <i>Lung Cancer</i> , <b>2012</b> , 78, 276-81	5.9	21
104	Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. <i>Oncologist</i> , <b>2012</b> , 17, 1376-85	5.7	21
103	Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemo-naïve patients with extensive-stage small-cell lung cancer. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1723-9	10.3	21
102	Applying Best-Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. <i>Lung Cancer</i> , <b>2012</b> , 77, 199-204	5.9	20
101	Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. <i>Clinical Oncology</i> , <b>2005</b> , 17, 591-8	2.8	20
100	Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis. <i>British Journal of Cancer</i> , <b>1999</b> , 81, 1037-41	8.7	20
99	Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA. <i>Cancer Letters</i> , <b>1996</b> , 104, 27-30	9.9	20
98	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , <b>2019</b> , 121, 144-153	7.5	19
97	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. <i>Melanoma Research</i> , <b>2011</b> , 21, 502-8	3.3	19
96	Emergency presentations in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , <b>2020</b> , 130, 193-197	7.5	16
95	Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2565-74	3.9	16
94	Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions. <i>Clinical Lung Cancer</i> , <b>2005</b> , 7, 23-9	4.9	16
93	The role for chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , <b>2017</b> , 4, 125-136	2.1	15
92	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , <b>2014</b> , 120, 2016-24	6.4	15
91	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. <i>Lung Cancer</i> , <b>2011</b> , 74, 75-9	5.9	14
90	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9524-9524	2.2	14
89	The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. <i>Nature Communications</i> , <b>2021</b> , 12, 4098	17.4	14

88	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	14
87	Adjuvant immunotherapy: the sting in the tail. <i>European Journal of Cancer</i> , <b>2020</b> , 132, 207-210	7.5	13
86	Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish. <i>Cancer Research</i> , <b>2019</b> , 79, 2136-2151	10.1	12
85	Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?. <i>Drugs</i> , <b>2006</b> , 66, 1919-31	12.1	12
84	Current drug treatment guidelines for epithelial ovarian cancer. <i>Drugs</i> , <b>1996</b> , 51, 571-84	12.1	12
83	Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 272-274	4.5	11
82	Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 87-95	4	11
81	Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor. <i>Gynecologic Oncology</i> , <b>2000</b> , 78, 92-6	4.9	11
80	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. <i>Nature Communications</i> , <b>2020</b> , 11, 853	17.4	10
79	A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 1547-50	7.5	10
78	Small cell carcinoma of the cervix. <i>Clinical Oncology</i> , <b>1996</b> , 8, 102-5	2.8	10
77	Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 2085-90	7.5	10
76	Septicaemia and septic arthritis due to <i>Pseudomonas putida</i> in a neutropenic patient. <i>Journal of Infection</i> , <b>1991</b> , 23, 346-7	18.9	10
75	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101601	2.2	10
74	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 81995-82012	3.3	10
73	Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. <i>ESMO Open</i> , <b>2018</b> , 3, e000317	6	9
72	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , <b>2015</b> , 16, 15-7	21.7	9
71	Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. <i>British Journal of Cancer</i> , <b>1997</b> , 76, 1382-6	8.7	9

70	Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5051s-5056s	12.9	9
69	A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). <i>Sarcoma</i> , <b>2002</b> , 6, 83-7	3.1	9
68	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 36, e505-e514	7.1	9
67	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 655-664	21.7	9
66	Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. <i>BMJ Case Reports</i> , <b>2018</b> , 2018,	0.9	9
65	Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 65	8.5	8
64	25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 793-800	8.7	8
63	MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy. <i>Leukemia and Lymphoma</i> , <b>1995</b> , 18, 297-302	1.9	8
62	Oestrogenic steroids and melanoma cell interaction with adjacent skin cells influence invasion of melanoma cells in vitro. <i>Pigment Cell &amp; Melanoma Research</i> , <b>2000</b> , 13 Suppl 8, 68-72		7
61	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e505-14	7.1	7
60	An open-label, multicentre safety study of vemurafenib in patients with BRAF-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , <b>2019</b> , 107, 175-185	7.5	7
59	Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma. <i>Ocular Immunology and Inflammation</i> , <b>2019</b> , 27, 1012-1015	2.8	7
58	The role of nivolumab in melanoma. <i>Future Oncology</i> , <b>2018</b> , 14, 1241-1252	3.6	6
57	Sequential immunotherapy regimens-expect the unexpected. <i>Lancet Oncology</i> , <b>2016</b> , 17, 854-855	21.7	6
56	A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update. <i>Ecancermedicalscience</i> , <b>2008</b> , 2, 108	2.7	6
55	DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9068-9068	2.2	6
54	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9501-9501	2.2	6
53	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 651-660	7.1	6

52	Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 395-396	19.4	5
51	The place of PD-1 inhibitors in melanoma management. <i>Lancet Oncology</i> , <b>2015</b> , 16, 873-4	21.7	5
50	Dabrafenib and its use in the treatment of metastatic melanoma. <i>Melanoma Management</i> , <b>2015</b> , 2, 199-208		5
49	Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. <i>British Journal of Haematology</i> , <b>2007</b> , 137, 436-42	4.5	5
48	Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. <i>British Journal of Cancer</i> , <b>2003</b> , 88, 1335-8	8.7	5
47	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , <b>2018</b> , 9, 34617-34627	3.3	5
46	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 156-168	7.5	5
45	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 651-660	7.1	4
44	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. <i>Lung Cancer</i> , <b>2011</b> , 73, 338-44	5.9	4
43	Radiotherapy in extensive-disease small cell lung cancer. A survey of current UK practice. <i>Clinical Oncology</i> , <b>2009</b> , 21, 78	2.8	4
42	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA9000-LBA9000	2.2	4
41	Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes. <i>Cancer</i> , <b>2018</b> , 124, 4731	6.4	4
40	Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis. <i>Practical Radiation Oncology</i> , <b>2016</b> , 6, 110-3	2.8	3
39	Melanoma vaccines--they should work. <i>Annals of Oncology</i> , <b>2006</b> , 17, 539-41	10.3	3
38	Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial. <i>Expert Review of Anticancer Therapy</i> , <b>2007</b> , 7, 635-40	3.5	3
37	Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9027-9027	2.2	3
36	Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1712-3	10.3	2
35	Extensive-stage small-cell lung cancer--moving beyond response rate?. <i>Annals of Oncology</i> , <b>2009</b> , 20, 801-2	10.3	2

34	Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. <i>Pigment Cell and Melanoma Research</i> , <b>2009</b> , 22, 532-43	4.5	2
33	510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 162	1.6	2
32	Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma. <i>British Journal of Cancer</i> , <b>1995</b> , 72, 193-7	8.7	2
31	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101701	2.2	2
30	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. <i>ESMO Open</i> , <b>2020</b> , 5,	6	2
29	Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a Buy-Back Scheme. <i>Children</i> , <b>2021</b> , 8,	2.8	2
28	Reply to Comment on Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , <b>2017</b> , 116, e15	8.7	1
27	The role of chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , <b>2014</b> , 1, 173-184	2.1	1
26	Vemurafenib-induced nonautoimmune haemolytic anaemia. <i>Melanoma Research</i> , <b>2014</b> , 24, 418-9	3.3	1
25	Update on targeted therapies for small cell carcinoma of the lung. <i>Targeted Oncology</i> , <b>2008</b> , 3, 205-215	5	1
24	A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status. <i>Current Respiratory Medicine Reviews</i> , <b>2006</b> , 2, 59-66	0.3	1
23	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2006</b> , 53, 165-70	5.9	1
22	Palliative treatment. <i>Hematology/Oncology Clinics of North America</i> , <b>2004</b> , 18, 417-32	3.1	1
21	Circulating Tumour DNA in Melanoma-Clinic Ready?. <i>Current Oncology Reports</i> , <b>2022</b> , 24, 363	6.3	1
20	DGAT1 is a lipid metabolism oncoprotein that enables cancer cells to accumulate fatty acid while avoiding lipotoxicity		1
19	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1926-1934	7.5	1
18	T cell immune awakening in response to immunotherapy is age-dependent.. <i>European Journal of Cancer</i> , <b>2021</b> , 162, 11-21	7.5	0
17	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors Reply. <i>Lancet Oncology</i> , <b>2021</b> , 22, e343-e344	21.7	0

16	Patient engagement in melanoma research: from bench to bedside. <i>Future Oncology</i> , <b>2021</b> , 17, 3705-3716	6.6	o
15	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.. <i>European Journal of Cancer</i> , <b>2022</b> , 164, 62-69	7.5	o
14	Prognostic and predictive value of Tblockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.. <i>European Journal of Cancer</i> , <b>2022</b> , 165, 97-112	7.5	o
13	Nivolumab in treating advanced melanoma. <i>British Journal of Health Care Management</i> , <b>2016</b> , 22, 294-296	6.4	
12	Targeting angiogenesis in melanoma. <i>Expert Review of Dermatology</i> , <b>2009</b> , 4, 237-248		
11	Efficacy of positron emission tomography staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, e25; author reply e26	8.9	
10	Prise en charge du cancer bronchique [petites cellules (CPC) (localis[et tendu). <i>Revue Des Maladies Respiratoires Actualites</i> , <b>2009</b> , 1, 436-443		o
9	Monitoring neutrophil phagocytosis in lung cancer patients or normal stem cell donors, treated with G-CSF. <i>Biochemical Society Transactions</i> , <b>1997</b> , 25, 197S	5.1	
8	Small Cell Lung Cancer (SCLC); any progress?. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 398-399	1.6	
7	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. <i>European Journal of Cancer, Supplement</i> , <b>2005</b> , 3, 41-50	1.6	
6	Re: Small cell lung cancer treated in southeast Wales, Lester et al., Clin Oncol 2006;18:378-382. <i>Clinical Oncology</i> , <b>2006</b> , 18, 722-3	2.8	
5	Anti-Angiogenesis Therapy for Melanoma <b>2012</b> , 281-294		
4	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS8605-TPS8605	2.2	
3	AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA9000-LBA9000	2.2	
2	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 944-946	2.2	
1	Cutaneous Melanoma in Older Adults with Frailty <b>2022</b> , 383-401		